[A20-33] Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94
Last updated 14.05.2020
Project no.:
A20-33
Commission:
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy
Due to new information from the commenting procedure now hint of a non-quantifiable added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-94 | Belimumab (SLE) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-05-14 A G-BA decision was published.